Allergic rhinitis ‐ infant incidence · infants
It is very uncertain whether higher changes allergic rhinitis ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ Infancy (incidence) · infants
It is very uncertain whether higher changes food allergy ‐ infant incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
All allergic disease ‐ childhood (incidence) · infants
It is very uncertain whether higher changes all allergic disease ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Asthma ‐ childhood (incidence) · infants
It is very uncertain whether higher changes asthma ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Eczema ‐ childhood (incidence) · infants
It is very uncertain whether higher changes dermatitis/eczema ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
Food allergy ‐ childhood (incidence) · infants
It is very uncertain whether higher changes food allergy ‐ childhood incidence compared with lower PUFA intake (very low certainty).
1 finding from 1 review
HDL‐cholesterol · people with or without existing cardiovascular disease, men and women
1 finding from 1 review
Leaving the study early: insufficient response ‐ When compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in leaving the study early: insufficient response ‐ When compared with… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Global state: 1. No clinically important improvement ‐ CGI‐I ‐ when compared with high dose (greater than or equal to 10 mg/day) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) showed no clear difference in global state: 1. No clinically important improvement ‐ CGI‐I ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Mental state: No clinically important improvement · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower mental state: 1. No clinically important improvement ‐ PANSS ‐ when… compared with ANY DOSE ‐ short term (moderate certainty).
4 findings from 1 review
Show 1 more finding
Adverse effects: 5a. Movement disorders ‐ specific symptoms ‐ EPS: unspecified ‐ versus high dose ( greater than or equal to 10 mg) · patients with schizophrenia
STANDARD‐HIGHER DOSE (greater than or equal to 6‐<10 mg/day) probably leads to lower adverse effects: EPS: unspecified ‐ Versus high dose (greater than… compared with ANY DOSE ‐ short term (moderate certainty).
1 finding from 1 review
Smoking cessation · people who smoke
Higher‐dose showed no clear difference in smoking cessation ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (moderate certainty).
3 findings from 1 review
RR 1.09 [0.93, 1.29]
5 studies · 1655 participants
Moderate
RR 1.19 [1, 1.41]
3 studies · 3446 participants
Moderate
RR 1.48 [1.06, 2.08]
1 study · 537 participants
Moderate
SAEs · people who smoke
Higher‐dose showed no clear difference in overall SAEs ‐ 42/44 mg versus 21/22 mg (24 hr patches) compared with lower‐dose nicotine patch (low certainty).
2 findings from 1 review
Treatment withdrawal · people who smoke
Higher‐dose may leads to higher treatment withdrawals ‐ 42/44 mg versus 21/22 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
1 finding from 1 review
Treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) · people who smoke
Higher‐dose showed no clear difference in treatment withdrawals ‐ 21 mg versus 14 mg (24‐hour patches) compared with lower‐dose nicotine patch (low certainty).
1 finding from 1 review
Deaths · patients with acute organophosphate pesticide poisoning
It is very uncertain whether higher dose changes deaths compared with lower dose (very low certainty).
1 finding from 1 review
Intermediate syndrome · patients with acute organophosphate pesticide poisoning
It is very uncertain whether higher dose changes intermediate syndrome compared with lower dose (very low certainty).
1 finding from 1 review
Ventilated · patients with acute organophosphate pesticide poisoning
It is very uncertain whether higher dose changes ventilated compared with lower dose (very low certainty).
1 finding from 1 review
Caries experience (mean DMFT) · 12-year-old children across European countries (national/regional epidemiological surveys, 2011-2022)
Mean DMFT in 12-year-olds rises as national income falls: 0.90 (very high income), 2.38 (high income), 3.30 (middle income) (Figure 2); not GRADE-rated.
3 findings from 1 review
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by World Bank GNI per capita (modified 3-category); test of group differences Q_b(2)=51.35, p<0.01 · Very high income (GNI >$25,000)
MEAN 0.90 [0.66, 1.15]
14 studies
GRADE not reported
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by World Bank GNI per capita (modified 3-category); test of group differences Q_b(2)=51.35, p<0.01 · High income (GNI $15,001-25,000)
MEAN 2.38 [1.78, 2.97]
8 studies
GRADE not reported
Caries status in 12-year-old children, geographical location and socioeconomic conditions across European countries: A… 2025 All outcomesCross-sectional (survey data 2011-2022) · European countries stratified by World Bank GNI per capita (modified 3-category); test of group differences Q_b(2)=51.35, p<0.01 · Middle income (GNI <=$15,000)
MEAN 3.30 [2.57, 4.03]
12 studies
GRADE not reported
Circuit lifespana · AKI patients receiving CKRT
1 finding from 1 review